Choline C-11: Pulling back the curtain on prostate cancer May 22, 2014 Overview Show transcript Overview About 90,000 men annually seek treatment for recurrent prostate cancer, according to the Surveillance, Epidemiology, and End Results Program. Recurrent prostate cancer is defined as cancer that has recurred following initial therapy, which could include surgery, radiation therapy, hormone therapy or chemotherapy. Choline C 11 Injection has a short shelf life and must be made in a specialized facility and given to patients within minutes after production. Mayo Clinic has the integrated production, imaging and pathology facilities to provide the benefit of Choline C 11 PET imaging to patients. Receive Mayo Clinic news in your inbox. Sign up Related ContentVideo11C-choline PET/CT for parathyroid imagingArticle11C-choline PET/CT for parathyroid imaging VID-20439984 Medical Professionals Choline C-11: Pulling Back the Curtain on Prostate Cancer